Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting

PHASE4CompletedINTERVENTIONAL
Enrollment

425

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

October 31, 2011

Study Completion Date

December 31, 2011

Conditions
HIV-1 Infection
Interventions
DRUG

nevirapine

Nevirapine 200 mg twice daily or 400 mg once daily per os during 96 weeks

DRUG

ritonavir-boosted Lopinavir

ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily per os during 96 weeks

DRUG

Tenofovir/emtricitabine

tenofovir 300 mg/emtricitabine 200 mg fixed-dose combination once daily, per os for 96 weeks

DRUG

Zidovudine/lamivudine

zidovudine 300 mg/lamivudine 150 mg twice daily fixed-dose generic combination, per os for 96 weeks

Trial Locations (1)

Unknown

Cliniques Universitaires de Lubumbashi, Lubumbashi

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

University of Liege

OTHER

collaborator

Ministry of Public Health, Democratic Republic of the Congo

OTHER_GOV

collaborator

Pierre and Marie Curie University

OTHER

collaborator

University Paris 7 - Denis Diderot

OTHER

collaborator

Gilead Sciences

INDUSTRY

collaborator

Abbott

INDUSTRY

lead

Centre Hospitalier Universitaire Saint Pierre

OTHER

NCT01772940 - Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting | Biotech Hunter | Biotech Hunter